Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Post 20006 is a lovely message I got from WeeZuhl the lovely Physician ( or so he says he is). God if he is I feel so sorry for his patients.
DataStream, what is your faith in Susman Godfrey that they can pull this off and win a verdict against Activision? Also can Activision appeal it if they lose and try and drag it out more?
If Susman does win and Activision does pay will other suits follow fairly rapidly?
Thanks
Prove to this board when this was a .88 cent stock. As far back as May 2010 it's NEVER reached .88 cents. I think you're lost ole feller.
"I built a position here with several purchases in the 40 cent to 50 cent area going up and sold it all as it came down from its high--the last of my position was sold at 88 cents ---I am not yet back in---but I will be."
What ever happened to revenue from the NCSoft verdict?
I hope it drops to .01 before Nov. 10th I'll load up big time if she does. As long as we can stay away from the dreadful reverse split. God I hate those dang things. Seems like 95% of penny stocks end up doing one or two.
Thom best be selling everything he can find to keep this case alive and hitting up every possible avenue for more revenue that doesn't dilute the shares. Selling his house, car, dog, wife, kids, etc. Those can all be replaced.
I would surely think that Susman Godfrey was ready for the:
MOTION for Summary Judgment that the Asserted Patent Claims are Invalid under 35 U.S.C. 101
as a lot of Defendants have been filing that lately. Sad thing is a lot of them have been getting it granted.
Back in June 2013
A party moving (applying) for summary judgment is attempting to avoid the time and expense of a trial when the outcome is obvious. A party may also move for summary judgment in order to eliminate the risk of losing at trial, and possibly avoid having to go through discovery (i.e., by moving at the outset of discovery), by demonstrating to the judge, via sworn statements and documentary evidence, that there are no material factual issues remaining to be tried. If there is nothing for the factfinder to decide, then the moving party asks rhetorically, why have a trial? The moving party will also attempt to persuade the court that the undisputed material facts require judgment to be entered in its favor. In many jurisdictions, a party moving for summary judgment takes the risk that, although the judge may agree there are no material issues of fact remaining for trial, the judge may also find that it is the non-moving party that is entitled to judgment as a matter of law.
Activision is trying to get the case thrown from the courts before a trial date is set. Don't know if they accomplished that or not yet.
5 U.S. Code § 101 - Inventions patentable
Current through Pub. L. 114-38. (See Public Laws for the current Congress.)
US Code
Notes
prev | next
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Activision has filed
September 04, 2015 00:00
Statement of Material Facts L.R. 56.1
Document: 177
Statement of Material Facts L.R. 56.1 re 174 MOTION for Summary Judgment that the Asserted Patent Claims are Invalid under 35 U.S.C. 101 filed by Activision Blizzard, Inc., Activision Publishing, Inc., Blizzard Entertainment, Inc.. (Moffa, Matthew)
September 04, 2015 00:00
Affidavit in Support of Motion
Document: 176
AFFIDAVIT in Support re 174 MOTION for Summary Judgment that the Asserted Patent Claims are Invalid under 35 U.S.C. 101 filed by Activision Blizzard, Inc., Activision Publishing, Inc., Blizzard Entertainment, Inc.. (Attachments: # 1 Exhibit U.S. Patent No. 7,181,690, # 2 Exhibit U.S. Patent No. 7,493,558, # 3 Exhibit U.S. Patent No. 7,945,856, # 4 Exhibit U.S. Patent No. 8,082,501, # 5 Exhibit U.S. Patent No. 8,145,998, # 6 Exhibit Excerpts from the certified file history of U.S. Patent No. 8,082,501, # 7 Exhibit Excerpts from the certified file history of U.S. Patent No. 8,145,998, # 8 Exhibit Worlds Inc.s Sixth Supplemental Disclosure of the Claims Infringed (D.I. 160), # 9 Exhibit Courts Markman Order of June 26, 2015 (D.I. 153))(Moffa, Matthew)
September 04, 2015 00:00
Memorandum in Support of Motion
Document: 175
MEMORANDUM in Support re 174 MOTION for Summary Judgment that the Asserted Patent Claims are Invalid under 35 U.S.C. 101 filed by Activision Blizzard, Inc., Activision Publishing, Inc., Blizzard Entertainment, Inc.. (Moffa, Matthew)
September 04, 2015 00:00
Summary Judgment
Document: 174
MOTION for Summary Judgment that the Asserted Patent Claims are Invalid under 35 U.S.C. 101 by Activision Blizzard, Inc., Activision Publishing, Inc., Blizzard Entertainment, Inc..(Moffa, Matthew)
We're still around 2 years away from this getting settled.
We have a ways to go as we're not even on the Top 50 list yet but I see us being on it in 2016 and beyond.
http://www.pocketgamer.biz/list/60889/pocketgamerbiz-top-50-developers-2015/
I really like the CEO of this company. He seems like the type of person that will succeed. I see this company being right up there with the other top mobile gaming companies within 2 years. Possibly the TOP mobile gaming company.
"The notification from the FDA stated that the Company will not be required to conduct Phase III studies if bioequivalence to Oxycontin(TM) is demonstrated."
The bioequivalence required only has to do with Oxycontin so the PODRAS has NOTHING to be bioequivalent to.
I contacted the company asking them if a Phase 3 will be needed with the PODRAS added and will let you know what they respond.
"We are pleased with the grant by the FDA of Fast Track status for Rexista(TM) Oxycodone XR incorporating our proprietary PODRAS(TM) technology which is being formulated to decrease the 'liking' of dose escalation and decrease or delay the attendant risk of respiratory depression in drug-naive individuals. The development of this product candidate could, if successful, decrease the desirability of taking more intact tablets than prescribed, potentially addressing an unmet need and possibly resulting in fewer accidental or intentional deaths," stated Dr. Isa Odidi, CEO and co-founder of Intellipharmaceutics. "To the best of our knowledge, no other product currently approved for sale in the U.S. or Canada has demonstrated this potential."
"We are pleased with the grant by the FDA of Fast Track status for Rexista(TM) Oxycodone XR incorporating our proprietary PODRAS(TM) technology which is being formulated to decrease the 'liking' of dose escalation and decrease or delay the attendant risk of respiratory depression in drug-naive individuals. The development of this product candidate could, if successful, decrease the desirability of taking more intact tablets than prescribed, potentially addressing an unmet need and possibly resulting in fewer accidental or intentional deaths," stated Dr. Isa Odidi, CEO and co-founder of Intellipharmaceutics. "To the best of our knowledge, no other product currently approved for sale in the U.S. or Canada has demonstrated this potential."
It doesn't get any better than to have the CFO buying common stock. He knows the company better than the CEO
The Will to Win
At Susman Godfrey, we want to win because we are stand-up trial attorneys, not discovery litigators. We approach each case as if it is headed for trial. Everything that we do is designed to prepare our attorneys to persuade a jury. When you are represented by Susman Godfrey, the opposing party will know that you are willing to take the case all the way to a verdict if necessary; this fact alone can make a good settlement possible.
Susman Godfrey has a longstanding reputation as one of the premier firms of trial lawyers in the United States. We are often brought in on the eve of trial to "rescue" troubled cases or to take the reins when the case requires trial lawyers with a proven record of courtroom success.
We also want to win because we share the risk with our clients. We prefer to work on a contingency-fee basis so that our time and efforts pay off only when we win. Our interests are aligned with our clients-we want to achieve the best-possible outcome at the lowest possible cost.
Finally, we want to win because each of our attorneys shares a commitment to your success. Each attorney at the firm — associate as well as partner — examines every proposed contingent fee case and has an equal vote on whether or not to accept it. The resulting profit or loss affects the compensation of every attorney at the firm. This model has been a tremendous success for both our attorneys and our clients. In recent years, we have achieved the highest profit-per-partner results in the nation. Our associates have enjoyed performance bonuses equal to their annual salaries. When you win, our attorneys win.
http://www.susmangodfrey.com/Why-Susman-Godfrey/
The only reason I invested in this stock to begin with back in 2013 was because of Susman Godfrey and them only. From what I've read Thom Kindred or what ever his name is, is that he's a prick. I could care less about Worlds, Inc. and their balance sheet, RS, funding (cause they aren't doing anything now anyway where funds are a big issue being Susman is on contingency), etc. I just know Susman Godfrey plans their WHOLE attack on getting to trial and when they do they DOMINATE the court room. So as far as the stock price going down? More the better. I can buy more. Cause everything is going as planned for Susman Godfrey, they've got their day in court coming up and that's all they've been waiting for. Their track record speaks for itself.
I'm going to hold out for the long haul on this one. Meaning if they win against Activision they'll surely go after all the other infringers and those I'd say will settle out of court so that shouldn't drag out for years. This thing has a chance to be a $5 stock in a couple of years. Might sell enough after a positive markman to get my initial investment back then just let the rest ride
Working with the Chinese on getting the labs digitized over there will be a huge revenue maker
This Lab-In-One Automation could be their blockbuster product.
MEDITE Cancer Diagnostics, Inc. Announces Granted Patent “Lab-in-One Automation” System
Orlando, FL, – March 20, 2015 – MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and related diseases announced the recent decision of the German Patent Register to grant MEDITE the German priority patent for its Histology “Lab-in-one Automation” System. Based on this success MEDITE will finish its nationalization applications for USA, China and UK before April 4th, 2015.
Similar to the highly automated clinical laboratory industry, the anatomic pathology laboratory industry is about to undergo an automation transformation. MEDITE’s new patent serves again as the forerunner in transitioning the industry towards automation. This “Lab-in–One Automation“ technology will revolutionize the automation of pathology laboratories by combining many disparate systems into one complete automated histology laboratory. Biopsies are automatically processed into microscopy slides ready for diagnosis and digitalization.
The “Lab-in-one Automation” fully automates 24 by 7 tissue processing, embedding, sectioning, staining, cover-slipping and digital slide scanning according to Michaela Ott, CEO of MEDITE.
The patented “Lab-In-One” device, which utilizes state of the art robotic and laser technology, is designed to fulfill the need for increased volume throughput emanating from increased demand from large laboratories in the US and other countries, including highly populated countries like China. This innovative technology reduces the cycle time from 24 to 48 hours down to 1 hour for up to 400,000 slides per year. The technology is based on MEDITE’s partially automated systems now combined into a new closed and computer controlled system including an automated sectioning device.
In successfully integrating these systems, we overcame significant technological hurdles. This technology also significantly integrates histology results into the digital Laboratory Information Systems as a method for fully documenting and supporting the diagnoses. MEDITE believes the “Lab-in–One Automation“ technology can serve as an integral factor for the standardization desired by most of the industry’s laboratories and customers. Most of the consumables currently used, and in particular the use of hazardous reagents for decalcifying and processing the biopsies like acids, xylene and formalin, are no longer needed which significantly improves the laboratory working environment. The operating costs of running an average histology lab can be reduced by over 50% from existing levels.
MEDITE is strategically positioned to meet the demand for more efficient and less costly medical care solutions in cancer diagnostics, along with addressing the current shortage of trained histotechs. We expect to start marketing the “Lab-in–One Automation” systems reflecting this leap in technology in the next 2-3 years contingent upon the availability of developmental resources. The 20 years patent protection securing MEDITE’s proprietary technology should allow the company to obtain a major portion of this billion dollar market.
About MEDITE Cancer Diagnostics, Inc.
MEDITE Cancer Diagnostics Inc., is a Delaware registered company consisting of wholly-own MEDITE GmbH a Germany-based Company with its subsidiaries CytoGlobe GmbH (Cytology Products, Germany), MEDITE GmbH (Austria), MEDITE Lab Solutions, Inc. (Distributor, Americas) and MEDITE sp. z o.o. (R&D Poland). Since 1978, MEDITE Group has specialized on the development, manufacture and distribution of medical laboratory automation equipment and supplies for pathology, histology and cytology. For these fields, the Company offers a complete range of devices and consumables. MEDITE currently sells into more than 70 countries and is the market leader in Germany. Through CytoGlobe, a wholly owned subsidiary, MEDITE offers a full range of products for Cytology labs. Additional information on MEDITE’s products and services can be found at www.medite-group.com. On April 3, 2014, MEDITE was purchased by CytoCore, Inc. a bimolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. The name and stock symbol of the company changed from CytoCore to MEDITE Cancer Diagnostics, Inc. in early December 2014.
Investor Contact:
Robert McCullough, Jr. CFO
Phone: +1 407 996 9630
Email: info@medite-group.com
MEDITE CANCER DIAGNOSTICS, INC. REPORTS 2014 YEAR END RESULTS ALONG WITH EXPECTATIONS FOR 2015
Orlando, FL, May 11, 2015 – MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces 2014 results and expectations for 2015.
In 2014, MEDITE Enterprise, Inc., with its subsidiaries in Germany, Austria and Poland, transformed through its purchase by CytoCore, Inc. from a privately owned company into a public company with a well know brand, 76 employees and an existing distribution network into about 70 countries.
MEDITE is now recognized as an up and coming competitor in the multibillion dollar anatomical pathology and cytology global market. MEDITE’s products improve the process and quality of cytology and histology methods and tools used for risk assessment and the diagnosis of cancer or precancerous conditions. The company is focused on becoming a global manufacturer of total histology and cytology solutions. The synergies resulting from the combined extensive research, knowledge, experience and developments of CytoCore Inc., with the engineering and marketing capabilities of MEDITE, should significantly expand product offerings and addressable markets for the new MEDITE.
“We are pleased MEDITE’s core business increased revenue, and remained operationally profitable, while obtaining very promising research and development technology from CytoCore, which should be an integral factor as MEDITE becomes an innovative force in cancer diagnostics. While reducing CytoCore’s operational losses by 50%, we made significant investments and achievements in the following new markets, products and developments:” commented Michaela Ott, CEO of MEDITE Cancer Diagnostics, Inc.
Microtomes and Cryostats
New manufacturing methods will enable MEDITE to increase its product gross margin while keeping the highest level of precision. These machines, which address approximately a $90 million market, are used to section human tissue into a few micron thin slices for optical microscope cancer screening. The new specially designed manual microtome specifically targets emerging countries, while the new Cryostat is designed to set new standards in compact size and low energy consumption.
Twister – Film-Coverslipper
This highly demanded new type of instrument is able to coverslip microscopic slides at speeds of up to 1,200 slides per hour. The current average glass-coverslipper on the market can only coverslip an average of 200 slides per hour. Our Twister perfectly complements our own CytoTape and could increase market share globally.
CytoTape – Coverfilm
MEDITE becomes the third participant in an approximate $60 million market dominated currently by one supplier. This product replaces glass as the protective cover of microscopic slides and allows for far quicker slide processing.
Chinese Market Collaboration
We achieved another major goal in 2014 with our market entrance into China. In our opinion, China is the fastest growing and, by 2016, one of the largest market places for our products. With our Chinese distributor, UNIC Medical, we successfully received Chinese Food and Drug Administration (“CFDA”) approval for all MEDITE histology laboratory devices.
The CFDA application for the cytology product line currently is in preparation, and approval is expected in 2015. The UNIC sales team has already successfully started selling the MEDITE histology products in China. During the first quarter we’ve already received purchase orders for approximately $500,000. Furthermore, we are planning with UNIC, as part of a government initiative, to standardize the histology laboratory process using MEDITE equipment, consumables, immuno-assays, along with the approved UNIC scanning technology for digitalization and computer aided diagnostics utilizing the latest cloud technology. UNIC Medical is a subsidiary of UNIC Group, a high tech company focused on automated digital optical quality assurance technology.
Cancer Risk Assessment Immuno-Assays and Special Stains
MEDITE has developed an innovative cytology stain and immuno-assays to be used for the detection of cancer and precancerous cells. Conventional tests, such as those used in the standard PAP test for cervical cancer, don’t utilize special stains; therefore abnormal cells can blend with normal cells and may potentially avert detection.
In addition, our test significantly reduces the time for processing a Pap to under a minute from over 30 minutes, and reduces or eliminates the use of hazardous reagents. Our cancer risk assessment immuno-assays developed over the last few years are showing excellent results in internal studies, but have not been tested yet in formal clinical trials.
This new immuno-assay, with our new special stain applied with our proprietary image recognition software, “highlight” specific cells to appropriately identify abnormal cells. Among others, we believe healthcare practitioners can utilize MEDITE’s solution to supplement existing PAP test methods.
In our opinion, one of the tests based upon our immuno-assays has the potential for displacing the expensive Human Papilloma Virus (HPV) testing methods. MEDITE’s enhanced test potentially improves the accuracy of patient diagnosis and reduces costs associated with unnecessary testing. We aim to start marketing this test globally outside the United States in 2015, and in the United States by 2017.
BreastPap
Independent studies confirm the analysis of female breast nipple aspirant, or the detection of abnormal cells, can be a useful risk analysis procedure for further evaluation of breast cancer for women between the ages of 20 and 45, when in most cases mammography is not appropriate. For them, it is a simple and affordable way to receive information about their breast cancer risk based a noninvasive method. MEDITE will soon test a prototype of an inexpensive breast aspirant collection device. Collected cells drawn from this device or fluids from the breast aspirant needle procedure can therefore be tested with the MEDITE assays and quickly evaluated for the possibility of cancer or precancerous conditions.
We believe a market of 300 million women currently exists for the application of MEDITE’s assays for either the “breast pap” or fine needle aspirant procedures in countries where testing is currently affordable and reimbursed. First market entries are planned in Europe and Asia using MEDITE’s CE mark.
Standard Histology Staining Solution
Our highly innovative newly developed staining solutions for histology and cytology are fulfilling modern needs for digitalization, computer aided diagnosis, and therefore can set a new standard in the industry around the world. It can replace the currently used Hematoxylin and Eosin stains, and in addition can reduce or eliminate laboratories’ use of environmentally hazardous reagents like xylene or formalin.
Histology Lab-in-One Patent
Similar to the highly automated clinical laboratory industry, the anatomic pathology laboratory industry is about to undergo an automation transformation. This highly innovative patented method will serve the industry in transitioning towards automation. Biopsies could be automatically processed into microscopic slides for diagnosis and digitalization. This Lab-in–One-technology, has the ability to change the competitive landscape within the industry.
We believe these significant investments in marketing, research and development as indicated in our results of operations for 2014 shown below, provide the launch for an exciting growth company looking to significantly increasing participation and market share in a dynamic multibillion industry.
Total revenues of $11 million for the fiscal year ended December 31, 2014 represented an increase of 10% from 2013. This increase was mainly a result of the growing sales of the recently launched cytology product lines to $1,852,000 (+38 %) and the growing revenue in the USA to $1,396,000 (+107%).
Cost of revenues represents the cost of the product sold, freight, and other costs of selling our products, totaled $7.16 million compared to $5.75 million for the year ended December 31, 2013. This mainly resulted from a higher percentage of distributor versus direct sales compared to the previous year.
Research and development expenses increased to $1.24 million compared to $934,000 for 2013. This increase of $309,000 or 33% is the result of the expenses associated with the former CytoCore, Inc. during 2014. MEDITE’s stand-alone funding for research and development, not including the contribution from CytoCore, Inc., increased $115,000 for year 2014 versus year 2013.
The operating loss of $394,000 of 2014, compared to the operating profit of $294,000 in 2013, resulted primarily from the inclusion of the $638,000 in operating expenses from the former CytoCore.
The net loss for the year ended December 31, 2014, totaled $699,000 as compared to net income of $54,000. As noted above, the primary reason for the loss was the inclusion of the results of operating expenses, including research and development associated with the former CytoCore’s operations, and increased income tax expense resulting from expensing the $129.452 deferred tax asset previously capitalized at December 31, 2013.
The reasons I invested in this patent case stock is because of Susman Godfrey's track record in patent trials, that they took something like 9 months reviewing the case before taking it on contingency and that Worlds went to Activision to discuss licensing years ago (that right there would be a huge issue if the case makes it to trial).
The Hudson Bay issue was a tough blow to the company but can be overcome. I seriously doubt if the Bungie filing succeeds at invalidating the patents as I'm sure Susman Godfrey did major DD on the patents before taking on the case.
With Bungie filing that the patents are invalid I'd say even with a positive Markman ruling this won't go up over .20 cents. This is still a long way from being over.
I'm not going to believe any ruling will be out within the next month. Not to be a Negative Nancy but I'd say she was just trying to keep him from bugging her about the ruling so she had to say something to keep him happy.
MarkmanRunup, do you think the case filed by Bungie about the patents being invalid will hold up?
beings we have billions at stake Judge Casper has probably decided her ruling long ago but is just waiting around to release it so it looks like she put a LONG time and effort into it
Casper sure ain't no friendly Ghost!
I sure hope we don't see a dang reverse split. Hopefully this runs to $1+ so if there is one it's a small one, like 1 for 2
Nice Pipe dream pump.
What happened to the short squeeze you spoke of? That was almost two months ago you stated they will be squeezed soon enough. Little off there are you?
Nice to see the Germans merge with CytoCore, they'll get their products on the market for them. Something Cytocore couldn't do in over 14 years!
No I read it. He's been blowin' hot air for months on here. If he's from Toronto and isn't worried about the SEC then give up CONCRETE info and stop the "Winky" "YouTube" BS.
tony tony tony, don't look like Santa dropped off the christmas gift you spoke of. Hummm maybe tony don't know so much. maybe tony full of hot air. sure seems that way. wish he was speaking truth but seems to be just another message board blow hard.
2015 is going to be a very exciting and profitable year for Medite. If they can get the breast cancer detection device that Cytocore was working on to market that would be very nice. Place it in every clinic like Walgreens Wellness Centers and CVS Minute Clinics, etc and in Doctor offices. Also the China agreement is exciting too!
http://www.medite-group.com/newsdetails.html?&tx_ttnews%5Btt_news%5D=79&tx_ttnews%5BbackPid%5D=1&cHash=67fa722f74c9f5ecd72bfea578d61fd3
To all the old Cytocore shareholders that have held for EVER and a DAY, (like 10 years+ for some) I truly believe the long wait is finally OVER!
Hey Winky Tony looks like Dec 10th passed. Looks like the terds are falling around here. Someone is REALLY full of them.
Will be Nice to see IPCI go up a DOLLAR or MORE in the next 10 DAYS of the month of December or sooner ............... Wink (DEC 10th)